IL6 and rheumatoid arthritis: Guiding principles from EULAR and ACR suggested that RA patients should continue treatment during COVID-19 and to allocate adequate supplies of IL-1 and IL-6 and JAK antagonists for especially those RA patients, in whom even brief drug holidays would be expected to cause a flare of their disease [129,130,131,132].